Abstract: An urban air mobility system includes aerial vehicles, a detection platform, and a fusion platform. The aerial vehicles include one cooperative aerial vehicle and one data consuming aerial vehicle. The detection platform detects a position of flight objects and transmits first data indicative of the position of the detected flight objects to the fusion platform. The cooperative aerial vehicle detects a relative position of flight objects in its surroundings and transmits second data indicative of the relative position of detected flight objects to the fusion platform. The fusion platform fuses the first data and the second data and generates an air traffic scenario. The data consuming aerial vehicle and the cooperative aerial vehicle receive the air traffic scenario from the fusion platform.

Abstract: A terminal for free-space optical communication, with a transmitting part generating first laser signals with a phase and/or amplitude encoded for forming a first laser beam, a beam combiner part forming the first laser beam by coherently combining, transmitting the first laser beam towards a target through an atmospheric channel, receiving a second laser beam having an altered second spatial beam pattern, and spatially dividing the second laser beam into a plurality of second laser signals, a receiving part configured to detect a phase and/or amplitude of second laser signals for determining a altered second spatial beam pattern, and a controller for determining the altered second spatial beam pattern by analyzing the second laser signals, estimate a first spatial beam pattern to be applied to the first laser beam as an estimated eigenmode of the atmospheric channel based on the second spatial beam pattern.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: An urban air mobility system includes aerial vehicles, a detection platform, and a fusion platform. The aerial vehicles include one cooperative aerial vehicle and one data consuming aerial vehicle. The detection platform detects a position of flight objects and transmits first data indicative of the position of the detected flight objects to the fusion platform. The cooperative aerial vehicle detects a relative position of flight objects in its surroundings and transmits second data indicative of the relative position of detected flight objects to the fusion platform. The fusion platform fuses the first data and the second data and generates an air traffic scenario. The data consuming aerial vehicle and the cooperative aerial vehicle receive the air traffic scenario from the fusion platform.

Abstract: A method for assisting in designing a technical system by: receiving an input message; processing the input message using a neural network to identify a content of the input message and extract technical system requirements, wherein the technical system requirements include at least a component having at least one parameter and a constraint; generating a proposed system design by determining at least one parameter of the component based on the constraint using the neural network; generating a response message containing the proposed system design using the neural network; and providing the proposed system design, wherein the neural network is configured as a large language model, LLM, and trained with a plurality of template systems and template components in the related technical field.

Abstract: A method for assisting a worker in a production line by: receiving a vocal input message from the worker; converting the vocal input message into a text input message; processing the text input message using a neural network to identify the content of the text input message and extract a request about at least one item related to the production line, wherein the neural network is configured as a large language model, LLM, and trained with information about the items of the production line; generating a response message containing information about the item of the production line using the neural network; converting the response message into a vocal response message; and providing the vocal response message to the worker.

Abstract: A method for assisting a trainee during a pilot training on a pilot training simulator, comprising receiving a vocal input message from the trainee; converting the vocal input message into a text input message; processing the text input message by a neural network configured as a large language model, LLM, to identify the content of the text input message and extract at least a request related to the pilot training simulator; accessing and searching a database based on the request to determine an educational advice using the neural network, wherein the database includes data about an aircraft on which the pilot training is performed; generating a response message containing the educational advice using the neural network; converting the response message into a vocal response message; and providing the vocal response message to the trainee.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an 1DO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.